^89Sr治疗骨转移瘤后韧致辐射显像的临床应用  

Therapeutic evaluation on bremsstrahlung imaging after ^89Sr administration in patients with bone metastases

作　　者：姜季[1] 荣国艳[1] 王兴华[1] 崔亚利[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院核医学科,哈尔滨150081

出　　处：《实用肿瘤学杂志》2010年第3期234-237,共4页Practical Oncology Journal

摘　　要：目的探讨应用韧致辐射原理显像，并监测放射性药物^89Sr治疗骨转移瘤后在患者体内的吸收分布情况及判断预后的可行性。方法经静脉注射放射性药物^89Sr的患者于治疗后1周进行韧致辐射显像．并与^89Sr治疗前所进行的^99mTc-亚甲基二膦酸盐（MDP）骨显像所得的图像进行对比。然后勾划感兴趣区（ROI）计算摄取最浓的病灶处和对侧或周围正常部位的放射性比值（T／NT比值）。并随访其疼痛缓解程度。结果89^Sr韧致辐射显像与^99mTc—MDP骨显像对照，所发现的病灶浓聚部位基本吻合。但与后者相比，^89Sr韧致辐射显像图像分辨率较差且解剖部位亦显示不佳，尤其是肋骨、小病灶处和^99mTc—MDP显像所示的放射性轻度浓聚灶。计算所得的T／NT比值约为3．13±1．03（1．24—5．81）。在后期随访中，^89Sr韧致辐射显像中T／NT比值较高的患者，其疼痛等症状缓解程度也较为明显。结论利用韧致辐射原理进行显像能够监测纯β发射体放射性核素^89Sr在患者体内的分布情况，并可以通过计算T／NT比值，再佐以患者疼痛的缓解程度可以初步判读预后情况。Objective To explore and analyze imaging by bremsstrahlung phenomenon after ^89Sr administration in patients with bone metastases. And then monitoring distribution of the bone - seeking radiopharmaceutical SgSr in body and evaluating the feasibility of the method. Methods Bremsstrahlung imaging was performed in 15 patients in the 7th day after ^89Sr administration and there was eumparision between it and ^99Tc - methylene bisphosphonate （MDP）hone scans. The region of interest（ROI） was outlined and then target/non -target ratio（ T/ NT ratio）was calculated. And a follow - up was made to observe thesis ache alleviation degree. Results Images gotten by ^89Sr bremsstrahlung imaging are similar to those by ^99mTc- MDP bone imaging,but the image reslution is less than the latter. T/NT ratio was about 3.13 ± 1.03 （ 1.24 - 5.81 ）. Conclusion With skeletal metastases through calculating T/NT ratio, and with pain relief degree, ^89Sr bremsstrahlung imaging for monitoring distribution of the bone - seeking radiopharmaeeutical ^89Sr in body is feasibility. And it can preliminary decide prognosis of the patients.

关 键 词：骨转移瘤 放射性核素锶-89(^89Sr) 韧致辐射显像 放射性核素治疗 

分 类 号：R730.55[医药卫生—肿瘤]